Foresite Capital Management IV, LLC
Position in XENE — Xenon Pharmaceuticals Inc.
CIK 1704132
West Hollywood, CA
Position in XENE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$9,657,600
+$353,600 QoQ
Shares Held
160,000
0.0% QoQ
Ownership
0.165%
of shares outstanding
% of Portfolio
3.33%
of 13F equity value
Holder Rank
#93
of 314 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in XENE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Foresite Capital Management IV, LLC holds $290,151,347 across 6 Biotechnology names. XENE ranks #5 (3.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PHVS |
Pharvaris N.V.
|
4,778,581 | $165,243,330 | |
| 2 | CYTK |
Cytokinetics Inc
|
714,695 | $60,884,867 | |
| 3 | EIKN |
Eikon Therapeutics, Inc.
|
1,943,682 | $25,365,050 | |
| 4 | RLAY |
Relay Therapeutics, Inc.
|
1,250,000 | $23,387,500 | |
| 5 | XENE |
Xenon Pharmaceuticals Inc.
This page
|
160,000 | $9,657,600 | |
| 6 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
150,000 | $5,613,000 |
All Filings in XENE
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $9,657,600 | 160,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $9,304,000 | 160,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $7,171,200 | 160,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $6,424,000 | 160,000 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $5,008,000 | 160,000 | Shares | Sole | 2025-08-12 | |
| No filing history on record for this holder in this stock. | ||||||